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Abstract
Background: Chagas disease (American trypanosomiasis) is a zoonotic or anthropozoonotic disease caused by the parasite
Trypanosoma cruzi. Predominantly affecting populations in poor areas of Latin America, medical care for this neglected
disease is often lacking. Me ´decins Sans Frontie `res/Doctors Without Borders (MSF) has provided diagnostic and treatment
services for Chagas disease since 1999. This report describes 10 years of field experience in four MSF programs in Honduras,
Guatemala, and Bolivia, focusing on feasibility protocols, safety of drug therapy, and treatment effectiveness.
Methodology: From 1999 to 2008, MSF provided free diagnosis, etiological treatment, and follow-up care for patients ,18
years of age seropositive for T. cruzi in Yoro, Honduras (1999–2002); Olopa, Guatemala (2003–2006); Entre Rı ´os, Bolivia
(2002–2006); and Sucre, Bolivia (2005–2008). Essential program components guaranteeing feasibility of implementation
were information, education, and communication (IEC) at the community and family level; vector control; health staff
training; screening and diagnosis; treatment and compliance, including family-based strategies for early detection of
adverse events; and logistics. Chagas disease diagnosis was confirmed by testing blood samples using two different
diagnostic tests. T. cruzi-positive patients were treated with benznidazole as first-line treatment, with appropriate
counseling, consent, and active participation from parents or guardians for daily administration of the drug, early detection
of adverse events, and treatment withdrawal, when necessary. Weekly follow-up was conducted, with adverse events
recorded to assess drug safety. Evaluations of serological conversion were carried out to measure treatment effectiveness.
Vector control, entomological surveillance, and health education activities were carried out in all projects with close
interaction with national and regional programs.
Results: Total numbers of children and adolescents tested for T. cruzi in Yoro, Olopa, Entre Rı ´os, and Sucre were 24,471,
8,927, 7,613, and 19,400, respectively. Of these, 232 (0.9%), 124 (1.4%), 1,475 (19.4%), and 1,145 (5.9%) patients, respectively,
were diagnosed as seropositive. Patients were treated with benznidazole, and early findings of seroconversion varied widely
between the Central and South American programs: 87.1% and 58.1% at 18 months post-treatment in Yoro and Olopa,
respectively; 5.4% by up to 60 months in Entre Rı ´os; and 0% at an average of 18 months in Sucre. Benznidazole-related
adverse events were observed in 50.2% and 50.8% of all patients treated in Yoro and Olopa, respectively, and 25.6% and
37.9% of patients in Entre Rı ´os and Sucre, respectively. Most adverse events were mild and manageable. No deaths occurred
in the treatment population.
Conclusions: These results demonstrate the feasibility of implementing Chagas disease diagnosis and treatment programs
in resource-limited settings, including remote rural areas, while addressing the limitations associated with drug-related
adverse events. The variability in apparent treatment effectiveness may reflect differences in patient and parasite
populations, and illustrates the limitations of current treatments and measures of efficacy. New treatments with improved
safety profiles, pediatric formulations of existing and new drugs, and a faster, reliable test of cure are all urgently needed.
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Discovered 100 years ago in 1909, Chagas disease (American
trypanosomiasis) is an endemic disease of the Americas, caused by
infection with the protozoan parasite Trypanosoma cruzi. According
to varying estimates, there are about 10–15 million existing cases,
50,000 new annual infections, and 14,000 deaths per year [1–5].
Chagas disease primarily affects populations in low-income,
resource-poor areas, where health care is often lacking or difficult
to access.
The first initiatives for controlling Chagas disease focused
primarily on prevention through vector control and screening of
blood donors, but with limited resources directed towards
diagnosing, treating, and following up those already infected
either during or after vector control activities. In 1999, the
international medical humanitarian organization Me ´decins Sans
Frontie `res/Doctors Without Borders (MSF) started its first
program for the diagnosis and treatment of Chagas disease for
affected populations.
Through its Spanish, French, and Belgian sections, MSF
implemented six Chagas disease diagnosis and treatment programs
in Honduras, Nicaragua, Bolivia, and Guatemala, from 1999 to
2008, focusing on pediatric populations [6]. In addition to its field
programs, MSF helped develop information, education, and
communication (IEC) modules in Argentina, Colombia, and
Ecuador, and together with the Pan American Health Organiza-
tion (PAHO) produced a virtual medical training course for the
diagnosis and treatment of Chagas disease [7,8].
Since 1999, MSF has treated over 3,100 patients for Chagas
disease. Here we describe four programs run by MSF Operational
Centre Barcelona Athens (OCBA) in 1999–2008 in endemic areas
of Honduras, Guatemala, and Bolivia. We discuss the feasibility of
implementing such projects in resource-limited settings in remote
rural areas, through the analyses and validation of shared
programmatic components, drug safety, and treatment effective-
ness.
Methods
Settings and Populations
In collaboration with national health ministries, MSF imple-
mented Chagas disease diagnosis and treatment programs in three
rural districts and one periurban setting from 1999 to 2008. The
rural programs were in Yoro, Honduras (latitude 15.3, longitude
287.1) from 1999 to 2002; Olopa, Guatemala (14.6, 289.3) from
2003 to 2006; and Entre Rı ´os, O’Connor Province, Tarija, Bolivia
(221.5, 264.7) from 2002 to 2006. The periurban program was in
Sucre, Bolivia (219.0, 265.2) from 2005 to 2008. All four
programs were in areas with relatively poor populations who had
limited access to medical care, with the rural areas in remote,
difficult-to-access locations.
All four programs focused on pediatric and adolescent patients,
but with an increase in age group treated over time: Yoro, ,12
years old; Olopa and Entre Rı ´os, ,15 years; and Sucre, ,18
years. The increase in treatment age groups over time and projects
reflected MSF’s strategy to first diagnose and treat young children
and then expand these services to older children and adolescents.
These areas were selected for medical intervention based on
available T. cruzi seroprevalence information from national
Chagas disease programs and preliminary seroprevalence surveys
by MSF, presence of active vector control programs (indoor and
peridomestic residual spraying and entomological surveillance),
and limited health care access. Requirements for opening these
programs included health care structures (eg, clinics, laboratories,
offices, etc), equipment, supplies, and human resources at the
primary health care level for carrying out laboratory serodiagnosis
and storage of serum samples, together with immediate opera-
tional capacity for adequate diagnoses, treatment, and follow-up.
MSF helped provide equipment; contracted additional temporary
healthcare, logistical, and administrative staff, when needed; and
bought all necessary supplies. All the programs had close
interaction with national, departmental, and municipal programs
regarding vector control activities, entomological evaluation and
surveillance, and health education.
Essential Program Components
All the Chagas disease diagnosis and treatment projects shared
six principal, essential features directly assuring program feasibility
in remote, rural settings (Table 1):
1. Information, education, and communication (IEC): The
four main target audiences were community authorities, health
staff, key community figures (eg, teachers, religious leaders, etc),
and patient families. The first step was to learn about the local
reality and situation through published and reported information
and through direct contacts, and second step was to establish a
dialogue with different leaders and actors to design the correct
IEC approach taking into account socioeconomic and cultural
contexts. In each program, meetings to spread IEC messages
within the four target populations were held before screening
activities. A more focused IEC session on diagnosis and treatment
(especially on follow-up and adverse events) was given to families
prior to patient detection, confirmation, and treatment. Informed
consent forms signed by the patient’s family were compulsory
before inclusion in each program. After treatment, community
meetings were held to obtain feedback on activities.
2. Vector control: As a precondition for treatment in national
programs for Chagas disease, MSF involvement in vector control
activities was adapted to each country’s situation and capacity. In
Yoro, Honduras, MSF was directly involved in vector control
activities; in the programs in Guatemala and Bolivia, vector
control was directed by the national programs. Before starting
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Chagas disease was discovered 100 years ago by the
Brazilian physician Carlos Chagas. Predominantly affecting
poor populations throughout Latin America, recognition
and treatment of this parasitic disease are often neglected.
Since 1999, the international medical humanitarian aid
organization Me ´decins Sans Frontie `res (Doctors Without
Borders) has offered diagnostic and therapeutic care for
Chagas disease, and here we describe four of our
programs in Honduras, Guatemala, and Bolivia, 1999–
2008. The earliest programs focused on treating young
children and in subsequent programs expanded up to 18
years of age. We identified six program components
essential for project viability: information, education, and
communication; vector control; health staff training;
screening and diagnosis; treatment and compliance; and
logistics. The number of children and adolescents screened
for Chagas disease ranged from over 7,500 to nearly 25,000
in each program. Early analysis of cure rates ranged widely:
from 87% and 58%, respectively, in Honduras and
Guatemala, to 0%–5% in Bolivia. No deaths occurred in
any of the programs, though drug-related side effects
were observed in a quarter to half of all patients. Through
our findings and experience, we discuss the feasibility,
safety, and effectiveness of treatment programs for Chagas
disease in resource-limited settings.
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infestation rates of the given community had to be ,3% following
national protocols. If a child was found to be seropositive, the
family’s house was checked to be vector-free, with targeted
spraying if needed. Entomological surveillance in the community
(Puesto de Informacion de Vinchucas [PIV], or Vector Informa-
tion Post) was regularly performed.
3. Training of health staff: Chagas disease-oriented training of
health staff members was carried out for teaching specific
diagnosis and treatment skills, and how to communicate and
work with patient families to help ensure adherence and follow-up
and for early adverse event detection and rapid intervention.
4. Active screening and diagnosis: Active disease screening at
the community level was implemented in all four projects. In each
program, the whole population found in the municipality based on
target patient age group was screened. Different diagnostic
guidelines were established in the four projects depending on
agreed-upon protocols, field availability of tests, feasibility of
implementation, and expert technical advice. Screening and
diagnosis were implemented at the primary health care level.
5. Treatment and compliance, including family-based strate-
gies: Inclusion criteria for etiological treatment in all programs
were enrollment of children of different cut-off age groups, with
age groups expanded in newer programs as programmatic
experience and evidence were gained; patients in acute or recent
chronic phase (indeterminate form) regardless of transmission
route; populations within the catchment area of the project; and
signed, informed consent by parents or guardians. Exclusion
criteria included pregnant and lactating women; patients with
renal or hepatic impairment or failure; any severe or generalized
disease; and drug hypersensitivity.
Some weekly follow-up sessions were handled by doctors,
focusing on treatment initiation and addressing adverse reactions,
while the remainder of follow-ups were handled by nurses focused
on treatment compliance. When adverse events were unmanage-
able, a referral system including third-level hospitals was used,
with referred patients followed up on a daily basis. Defaulters to
follow-up visits were actively traced by health staff or community
health workers. Serological follow-up was emphasized among
patients at the time of initial result, with serum samples taken
before treatment initiation. Reinforcement messages for treatment
adherence were given with full course of treatment. All care was
provided free of charge.
Treatment and compliance included a family-based strategy in
which parents and guardians of patients were co-responsible for
daily drug administration, early detection of adverse events, and
requesting medical help for patient treatment withdrawal, if needed.
6. Logistics: Logistic activities focused on access to remote
communities and close monitoring and evaluation of vector
control measures. The supply chain for drugs and laboratory
reagents was maintained, as was storage of frozen samples for
serological testing. Community structures, such as schools, were
used for relevant activities, including community meetings, IEC
sessions, training, screening, and treatment follow-up. MSF
worked in close collaboration with national Chagas disease
programs in terms of logistics in all four projects.
Screening and Diagnosis
According to World Health Organization (WHO) recommen-
dations, diagnosis of Chagas disease was confirmed using two
different tests. In case of doubtful or discordant results, a third test
was used. Following national and regional recommendations, each
project used different tests, as follows.
Diagnostic testing for T. cruzi was performed by ELISA
(conventional and recombinant), indirect hemagglutination
(HAI), and, for exceptional confirmation needs, indirect immuno-
fluorescence (IFI). The source of reagents for ELISA was Wiener
or Biochile.
Table 1. Essential program components of Me ´decins Sans Frontie `res Chagas disease diagnosis and treatment projects in Central
and South America, 1999–2008.
Program Component Elements/Description Goals
Information, education, and
communication (IEC)
Learn local reality/situation through reports and direct contacts and establish
dialogue with key leaders and actors; informational meetings targeting four main
groups: community authorities, health staff, key community figures, and patient
families; focused sessions on diagnosis and treatment (follow-up, adverse events,
among others); informed consent forms; community feedback meetings
Design correct IEC approach based on local
socioeconomic contexts; provide insight
into cultural constraints and health-seeking
behaviors; raise public awareness of the
disease and of availability of diagnosis/
treatment services
Vector control Precondition for treatment in national Chagas programs, with varying levels of
MSF involvement, but always with participation/follow-up of information and
surveillance systems
National program collaboration; disease
prevention; prevention of re-infection
Health staff training Chagas-oriented training for health personnel Establish family commitment to treatment
and follow-up
Screening and diagnosis Active screening at community level; filter paper for testing in Yoro, Olopa, and
Entre Rı ´os; Chagas Stat-Pak RDT (whole blood) introduced in Entre Rı ´os and Sucre
Identify patients for treatment; optimize
diagnostic protocols
Treatment and compliance Inclusion criteria: cut-off ages (expanded over time/projects), acute or recent chronic
disease phase (indeterminate form); populations within catchment areas, informed
consent; exclusion criteria: pregnant or lactating women, renal or hepatic impairment,
severe and/or generalized disease, drug hypersensitivity; follow-up by doctors on
treatment initiation and adverse events, and by nurses on compliance; defaulters to
follow-up actively traced; importance of serological follow-up emphasized; follow-up
reinforcement messages; family-based strategy for compliance and adverse event
monitoring
Ensure treatment completion; monitor
adverse events; proper follow-up care;
family engagement
Logistics Physical, geographical access to remote communities; monitoring and evaluation
of vector control; use of community structures for meetings, IEC sessions, training,
screening, and follow-up
Access to patients; delivery of care to
remote areas
doi:10.1371/journal.pntd.0000488.t001
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tional ELISA using filter paper. Confirmation of diagnosis was
done with recombinant ELISA. Similarly, in Entre Rı ´os,
conventional ELISA and HAI tests were conducted, with
recombinant ELISA as the tiebreaker. When necessary, IFI was
used instead of HAI. Later in the Entre Rı ´os program, Chagas
Stat-Pak (Chembio Diagnostic Systems, Inc, Medford, NY) rapid
diagnostic test (RDT) was introduced for screening, using whole
blood samples, and all positive results were systematically
confirmed by conventional ELISA and HAI, and recombinant
ELISA used as a tiebreaker. In Sucre, screening was conducting
using Chagas Stat-Pak on whole blood. As in Entre Rı ´os, positive
results were confirmed using conventional ELISA and HAI, with
tiebreakers assessed via recombinant ELISA.
For conventional and recombinant ELISA, cut-off values were
calculated according to manufacturer recommendations by taking
the sum of the absorbance of all negative controls and adding this
to a constant factor (0.200 for conventional, 0.300 for recombi-
nant). Positive results were those samples with an optic deviation
(DO) above cut-off+10%. Negative results were those with DO
below cut-off210%. Doubtful results were those with DO between
(cut-off210%) and (cut-off+10%). For HAI, positive results were
those samples with reactivity for dilution $1/16 titration. Positive
reactions for dilutions at 1/2, 1/4, or 1/8 were considered cross-
reactive and false-positive; protocol called for these samples to be
treated with 2-mercaptoethanol 1% and HAI repeated. For
Chagas Stat-Pak RDT, positive results were those samples giving
two pink/purple lines, one in test area and one in control area, at
reading at 15 minutes (maximum 30 minutes). Tests with no line
visible in the control area were considered invalid, and these
samples were retested using a new device.
Quality control (QC) measures were systematically performed in
the programs. For RDT QC, for every 10
th negative RDT result,
venous blood was taken and sent to the laboratory for ELISA/HAI
testing. For ELISA/HAI QC, internal QC was performed using the
positive and negative controls present in the test kit (and a
performance checklist was also used for QC on the procedure itself).
Overall, 10% of positive samples and 10% of negative samples were
sent to the reference laboratory for external QC.
Treatment and Follow-up
T. cruzi-positive patients were treated with benznidazole 5–
7.5 mg/kg/day, 2 or 3 times per day over 60 days (maximum
300 mg/day; if necessary, the total dose was calculated and
divided for more than 60 days). In the four programs, counseling
for the parents/guardians of infected children as provided,
informing them of how to give treatment, potential treatment
benefits, risk factors, and adverse events, including how to proceed
if adverse events occur. Treatment and follow-up (at days 0, 7, 14,
etc) were provided by health staff, while daily drug tablets were
administered at home by the parenets/guardians. Treatment
adherence sheets were filled out by parents/guardians or patients.
In results analysis, a patient was considered as having completed
treatment when .30 days of treatment were accomplished.
Passive, and when necessary, active, weekly patient follow-up
was performed in all projects by physicians or nurses. When
necessary, more intensive and/or more frequent follow-up was
performed. Clinical presentation and adverse events were
recorded.
Adverse Events
The severity of adverse events was recorded at each follow-up
visit. Adverse events were classified as mild, moderate, or severe.
Mild adverse events were defined as those requiring no treatment
interruption. Moderate adverse events were defined as those
requiring temporary treatment interruption, with the patient
returning to treatment within 14 days. Severe adverse events were
defined as those requiring treatment stoppage. All adverse events
were evaluated by a physician, and symptomatic treatment was
given according to their type and severity. The types of adverse
events observed were as follows: dermatological, gastrointestinal,
and neurological.
Seroconversion
To assess seroconversion from positive to negative for T. cruzi
infection, the first post-treatment serologic evaluation was
generally conducted at 18 or 36 months post-treatment. Post-
and pre-treatment blood samples were processed simultaneously
using conventional ELISA. Negative results from conventional
ELISA were confirmed with recombinant ELISA. All ELISA tests
used serum or plasma samples. All pre-treatment samples (serum/
plasma) were aliquoted and frozen (without glycerin) at 220uC,
less than 24 hours after collection. All ELISA test results were
obtained using an ELISA reader (optical density visible in the
reader screen).
Based on WHO protocol, cure was defined as two non-reactive
ELISA tests (one conventional, one recombinant) performed on
the same sample on the same date. For patients with positive or
indeterminate results in the first evaluation, a second serology
evaluation was generally performed at 36 months post-treatment.
Statistical Analyses
Normalized differences in antibody titers were calculated in
consecutive assessment comparisons to pre-treatment baseline
values by using the following equation: (final antibody titers2ini-
tial antibody titers)/initial antibody titers)6100. Likewise, differ-
ences in T. cruzi antibody titers between pre-treatment baseline
and post-treatment control values were compared using Wilcoxon
ranked sum test, and negative seroconversion rates between 18
and 36 months after treatment were compared using McNemar
test. Mann-Whitney U-test and Kruskal-Wallis test were used to
compare differences in T. cruzi antibody titers, while Chi-square or
Fisher’s exact test were used to analyze negative seroconversion
and tendency to seroconversion rates according to age and gener.
95% confidence intervals for rate differences were calculated.
Statistical significance was set at 5%. All tests of significance were
two-tailed.
Ethics
Informed written consent was obtained before treatment from
parents or guardians of patients who tested positive. If parents/
guardians were illiterate, oral explanation was given, and consent
was obtained by fingerprint. All data were collected routinely and
managed confidentially. All the projects were discussed, reviewed,
and approved by the national Ministry of Health (MOH), with
MOH permission granted before starting each program.
Results
Program Summaries
Yoro, Honduras, 1999–2002. MSF opened its first Chagas
disease treatment program in 1999, in the rural district of Yoro,
Honduras. The program diagnosed and treated those ,12 years
of age. Vector control activities were carried out directly by MSF
in this program. In December 2002, the program was handed over
to the local health authorities.
From 1999 to 2002, 24,771 patients were tested for T. cruzi
infection (Table 2). Of these, 232 children were positive, giving a
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asymptomatic with indeterminate form, except for one child who
presented an acute infection with Roman ˜a’s sign (unilateral
periorbital edema).
A total of 231 patients (9 months to 12 years of age) was treated
with benznidazole. All patients received a full 60-day course of
treatment except for 1 acute case treated with a 30-day protocol, 3
cases in which treatment was stopped (at 43, 49, and 50 days) due
to adverse events, and 3 cases treated for almost a full course (53,
54, and 56 days of treatment). Since a 30-day treatment is
considered correct for acute cases, 98.7% (228/231) of patients
completed treatment.
Olopa, Guatemala, 2003–2006. In 2003, MSF started a
Chagas disease management program for patients ,15 years old
in the rural area of Olopa, Guatemala. From 2003 to 2006 (end of
MSF involvement), 8,927 children were screened, with 124 found
to be positive for T. cruzi infection, resulting in an estimated
seroprevalence of 1.4% in the department of Olopa (Table 1). All
diagnosed and treated children were asymptomatic in the
indeterminate form.
Of the 124 infected patients, 123 were treated with benznida-
zole. Of those started on treatment, 95% completed a full course of
therapy (58–60 days). Thirteen (10.5%) patients interrupted
treatment, but only 4 (3.2%) stopped treatment.
Entre Rı ´os, Bolivia, 2002–2006. MSF opened its first Chagas
disease program in Bolivia in 2002. In a rural area of Tarija
department, a highly endemic region for Chagas transmission, the
program aimed to treat all children ,15 years old.
A total of 7,613 children was screened, of whom 1,475 were
confirmed with T. cruzi infection, giving a seroprevalence rate of
19.4% (Table 1). Seroprevalence by age group was 5.0% in ,5
years old; 14.8% in the age group 5–9 years old; 31.0% 10–14;
and 51.7% 15–16. Of these, 1,409 patients began treatment, and
1,363 completed at least 30 days of treatment and 1,276
completed at least 55 days (standard course of treatment). A total
of 28 (2%) children stopped treatment due to adverse events.
Sucre, Bolivia, 2005–2008. In 2005, MSF started Chagas
diseasediagnosisandtreatment intwodistrictsofSucre,aperiurban
environment in Bolivia. Building upon previous programmatic
experience and striving to increase care to more patients with
Chagas disease, the age group for treatment was expanded up to 18
years old. In addition to expanding the treatment age group, this
program was unique in its introduction of RDTs as a diagnostic
screening tool, based on Bolivian national protocol (diagnosis with
Chagas Stat-Pak RDT and confirmation with ELISA). In 2007, the
opportunity was taken to perform a field evaluation of the use of
whole blood with Chagas Stat-Pak RDT [9].
A total of 19,400 children was tested in two districts of Sucre, of
whom 1,145 were positive for T. cruzi, resulting in a seropreva-
lence rate of 5.9% (Table 1). Seroprevalence by age group was
1.9% ,5 years old; 4.1% 5–9; 8.6% 10–14; and 14.2% 15–18. Of
these, 1,040 patients started benznidazole treatment. A total of 912
(87.7%) patients completed a full course of treatment, 18 of whom
completed after switching to nifurtimox (second-line treatment)
due to adverse events. A total of 61 (5.8%) patients (0% in ,5
years old; 8.6% 15–18) stopped treatment due to adverse
events.
Adverse Events
Drug safety was assessed by recording treatment-related adverse
events in terms of severity and type. In all four programs, most
adverse events were mild. No deaths due to treatment occurred in
any of the programs.
In the Central American programs in Yoro, Honduras and
Olopa, Guatemala, 50.2% and 50.8% of patients, respectively,
had adverse events related to treatment (Table 3). In Yoro, most of
the adverse events were mild, with no moderate cases and 3 severe
cases due to neurological adverse events (neuromuscular distur-
bances of the lower limbs after 6 weeks of treatment). The most
frequent adverse events were gastrointestinal disorders (26.8%,
mainly epigastralgia and/or abdominal pain, and less frequently
nausea and/or vomiting and anorexia), followed by dermatolog-
ical conditions (13.0%, mainly pruritus and less frequently
maculopapular exanthema) and neurological problems (10.4%,
mainly neuromuscular disturbances). In Olopa, 80.9% (51/63) of
the adverse events were mild, 14.3% (9/63) moderate, and 4.8%
(3/63) severe (2 neuromuscular and 1 cutaneous). Adverse events
were 26% dermatological in nature, 25% gastrointestinal, 23%
neuromuscular, and 26% other types. In both Yoro and Olopa, no
differences were seen in the proportion of adverse events
depending on age or sex (Chi-square test).
Lower rates of treatment-related adverse events were observed
in the Bolivian programs. In Entre Rı ´os, adverse events were
observed in 25.6% of treated children, with increasing risk in older
age groups (12% in ,5 years old; 25% 10–14). In Sucre, 37.9% of
patients had adverse events, also with increasing risk in older
groups (13.4% in ,5 years old; 50% 15–18). In Entre Rı ´os, 56%
of adverse events were dermatological, 25% digestive, and 18%
neuromuscular, of which 11% were mixed. In Sucre, 68.5% of
Table 2. Chagas disease patient diagnosis and treatment results of four Me ´decins Sans Frontie `res programs in Central and South
America, 1999–2008.
Yoro (Honduras) Olopa (Guatemala) Entre Rı ´os (Bolivia) Sucre (Bolivia)
Program duration 1999–2002 2003–2006 2002–2006 2005–2008
Age group (years) ,12 ,15 ,15 ,18
# patients tested 24,771 8,927 7,613 19,400
# patients positive at initial screening 256 124 1,475 1,179
# patients confirmed positive/infected 232 124 1,475 1,145
Seroprevalence (%) 0.9 1.4 19.4 5.9
# patients treated 231 124 1,409 1,040
Seroconversion rate (%) 87.1 58.1 5.4 0
doi:10.1371/journal.pntd.0000488.t002
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majority of side effects were mild, with risk increasing with age.
Six and 41 severe adverse events were reported in Entre Rı ´os
and Sucre, respectively. In these two programs, 1 case of Lyell
syndrome (toxic epidermic necrolysis) and 1 case of Stevens
Johnson syndrome were reported. Lyell syndrome occurred in a
13-year-old girl at day 34 of benznidazole treatment. In the weekly
follow-up, the patient showed a generalized itchy rash with good
general clinical status and was treated with oral antihistamine
drugs. Two days later, a MSF physician was contacted and visited
the child, who presented with high fever and general cutaneous
rash with infected pustules. The patient was given intravenous
fluids and ceftriaxone until admission to Tarija hospital. She was
managed and discharged after 7 days with good clinical
improvement.
Seroconversion Rates
Treatment effectiveness was measured by rates of seroconver-
sion in the patients. A marked difference was seen in the rates of
seroconversion between patients treated in the two earlier Central
American programs (Yoro, Olopa) compared with the two later
programs in South America/Bolivia (Entre Rı ´os, Sucre).
In Yoro, Honduras, seroconversion rate for T. cruzi was 87.1%
(202/232) at 18 months post-treatment, showing a high serocon-
version rate achieved in a relatively short period of time (Table 1).
At 36 months, seroconversion rate was 92.7% (215/232). In
Olopa, Guatemala, from available patient data (25.5% of the
treatment cohort), seroconversion at 18 months post-treatment
was 58.1% (18/31).
Seroconversion rates observed in Entre Rı ´os and Sucre in
Bolivia were much lower. Preliminary results of overall serocon-
version post-treatment was 5.4% (59/1,101) in Entre Rı ´os by up to
60 months post-treatment, with over 950 of the patients sampled
having had follow-up later than 18 months post-treatment.
Seroconversion rates were found to be lower in older age groups
compared with younger ones in Entre Rı ´os: 24.2% (16/66) ,5
years old; 4.6% (14/303) 5–9 years old; 1.9% (12/638) 10–14
years old, at 18–60 months follow-up. To date, of 276 patients
followed up between 9 and 27 months post-treatment, no patient
has been found to have seroconverted in Sucre.
Discussion
The 10-year operational experience of MSF in these four
programs in Honduras, Guatemala, and Bolivia demonstrates that
diagnosis and treatment of Chagas disease are feasible, relatively
safe, and potentially effective in low-income, resource-constrained
settings. Through the lessons learned from earlier studies [10,11]
and these MSF projects and their common, essential logistical
components, we propose that this programmatic approach is
feasible at the primary health care level and replicable in other
Chagas-disease endemic countries and regions, even in periurban
and remote rural areas. With proper coordination between
different stakeholders focused on integrated health care services
for Chagas disease, including national and regional programs, the
diagnosis and treatment of the disease in early chronic phases
(mainly indeterminate form) can be safely implemented and
should be deemed necessary for affected populations [12,13].
Etiological treatment of Chagas disease can and should be
integrated at the primary health care level because most patients
are near primary health care services, and the majority of patients
would be able to receive medical care at this level, taking into
account the proportion of Chagas patients with the indeterminate
form of the disease. In MSF’s programs, this implementation was
achieved in remote rural settings through the application of six
central features and criteria: IEC, vector control, health staff
training, logistics, screening/diagnosis, and treatment/compli-
ance, with family-based support.
IEC was a chief component of program strategies and is vital to
ensure treatment compliance and early detection of adverse
events, especially when providing care for populations with
differing cultures, practices, and modes of communication, among
others. IEC was crucial for raising awareness in the general
population about the disease (regarding transmission routes,
clinical manifestations, and treatment and prevention possibilities)
and inform patients and patient families that diagnosis and
treatment services were available.
Vector control carried out by national programs was also an
important program component and should be simultaneously
implemented with patient access to diagnosis and treatment
[14,15]. MSF involvement varied as projects progressed, depend-
ing on the need and capacity of national authorities and other
partners. After treatment, vector control was continued through
the national programs, but regular spraying every 6 months was
not always carried out. Community entomological surveillance
occurred regularly, but spraying for vector control was irregular at
times. Eliminating the vector from the environment and
households of patients and those at risk is critical.
Health staff training and family IEC for family-based treatment
monitoring were exceptional ways of both ensuring quality of
diagnosis and treatment compliance, as well as engaging the family
in the health care process. Diagnosis and treatment of Chagas
disease in all the projects relied on well-trained health personnel to
apply their medical skills to care for patients and to establish family
commitment to treatment adherence and follow-up care. With
minimum logistical capacity, especially support for outreach
teams, our program experience may be replicable in other
endemic areas.
Table 3. Benznidazole-related adverse events in four Me ´decins Sans Frontie `res Chagas disease treatment programs in Central and
South America, 1999–2008.
Program Adverse Events
Number of patients % of all patients treated Mild, % Moderate, % Severe, %
Yoro, Honduras 116 50.2 97.4 0 2.6
Olopa, Guatemala 63 50.8 80.9 14.3 4.8
Entre Rı ´os, Bolivia 361 25.6 79.5 18.8 1.7
Sucre, Bolivia 394 37.9 61.4 28.2 10.4
doi:10.1371/journal.pntd.0000488.t003
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diagnosis used differing diagnostic protocols adapted to the
contexts of each country/region. For diagnosis in our programs,
the two tests selected were the two with minimum acceptable
sensitivity and specificity (ideally 99–100%) and which could be
feasibly implemented at the primary health care level [6,16]. Filter
paper blood samples were used in the earlier programs mainly for
sensitivity and adapted ease of use (ie, no need for centrifugation,
relatively easy to supply/refill, portability) in remote rural settings.
We introduced the use of Chagas Stat-Pak RDT in the Bolivian
programs and carried out a field evaluation using whole blood
samples. Recent studies using this RDT have shown relatively low
sensitivity (93–94%) compared with conventional tests [9,17,18],
and this limited sensitivity must be considered in the use of this
test. A whole-blood RDT with high sensitivity would be ideal for
screening and diagnosis in resource-limited settings [19].
For treatment and compliance, a large number and proportion
of patients started and finished treatment according to protocol in
our programs, with over 90% of patients completing .55 days of
treatment. Access to treatment, follow-up, and referral of
complicated cases were successful elements of the protocol.
Relatively low dropout before treatment and low default rates
(mostly migrations of patients and adverse reactions) were
observed. However, in one program, Sucre, about 9% of
diagnosed patients did not start treatment. The main reasons for
this were migration, reluctance to start treatment (after counseling
and informed consent), pregnant or lactating mothers, and
treatment being offered by MOH national programs. Still, overall
we found that Chagas treatment and follow-up can be achieved
with adequately trained, sensitized, and motivated health staff and
family members in both rural remote and periurban settings. The
family-based approach for daily drug administration and compli-
ance was key for Chagas disease because of the length of therapy
and occurrence of adverse events.
Drug treatment was safely administered in these four
programs, with no deaths occurring due to adverse events.
Despite this, nearly half of all patients had some type of adverse
event, a few of which were severe, including 1 case of Lyell
syndrome, and 1 case of Stevens Johnson syndrome. Although
no previous studies of Chagas disease have reported either of
these syndromes, these two cases must be viewed in the context
of over 3,000 patients treated in the four programs, with no
deaths in even the most severe cases. The majority of adverse
event cases were treated with a reduced dosage of benznidazole
(to the minimum dose of 5 mg/kg/day) or temporary suspension
of treatment. The time of appearance, intensity, and clinical
patterns of adverse events were not different than those observed
in other experiences [20], except that we did not see any
hematological reactions (ie, no clinical manifestations such as
anemia, severe infection, or hemorrhage were observed to make
us suspect detrimental effects on bone marrow). However,
hematological reactions were only followed clinically, without
routine laboratory testing, due to issues of practicality under field
conditions. This therefore poses a limitation in that hematolog-
ical adverse events cannot be completely excluded, especially
since severe hematological reactions (such as bone marrow
suppression) can be asymptomatic. Proximal neuromuscular
adverse events presented later (after 35 days of treatment)
compared with other adverse event types, demonstrating
cumulative drug toxicity.
Overall, the large number of children and adolescents treated
and observed in the four programs (.3,100) provides valuable
insight into drug safety for current Chagas disease drug treatment.
Previous studies have reported experiences from lower numbers of
patients [10,21]. Of note, we observed sizeable variations in
reported adverse events in the study locations, namely between the
two programs in Central America (Honduras/Guatemala) and the
two in South America (Bolivia). In recording adverse events and
their severity in our four programs, observer bias no doubt played
a role. The identification and classification of an adverse event is
often dependent on the observing medical staff, and misclassifi-
cations were possible in the programs. We attempted to address
this by defining mild, moderate, and severe adverse events based
on whether treatment was temporarily interrupted or fully
stopped. Other biases in adverse event profiles may exist, such
as differences in early detection of side effects and more or less
intensive medication and management for adverse events.
While a well-designed program should be able to minimize risks
and ensure safe treatment, the lack of a non-toxic alternative drug
remains a major obstacle to wider access to treatment for both
adults and children. No pediatric formulation currently exists for
benznidazole (nor nifurtimox, the only other drug used for treating
Chagas disease), increasing risks of under- or overdosing in
children. For the youngest patients, cutting tablets and mixing with
water or other liquids for oral administration is difficult and has
important pharmacological implications in terms of absorption
and bioavailability.
The seroconversion rates detected in treated patients were
relatively high in the Central American projects, Yoro, Honduras
and Olopa, Guatemala, showing that therapy can clear T. cruzi
infection. However, seroconversion was far lower in the South
American Bolivian projects in Entre Rı ´os and Sucre. The findings
in Bolivia are similar to those reported from earlier studies in
Argentina and Brazil [22–25]. Also, seroconversion was detected
earlier in the Central American programs compared with the
Bolivian programs. Previous research has shown that in South
America seroconversion is sometimes not detected until 5–7 years
later [26]. Thus, the higher and earlier seroconversion we detected
in Central America supports previously reported findings [27] and
may have important public health implications.
The differences in seroconversion rates may be explained by a
number of reasons. One primary explanation may be based on the
presence of different parasite lineages in different geographic
regions, with T. cruzi type I predominating in Central America and
T. cruzi type II in South America, with varying degrees of overlap
[28]. Because of the potential differences in T. cruzi subtypes
present in Honduras and Guatemala compared with Bolivia, drug
treatment effectiveness may have differed. Another factor to
consider is the time between vector control activity and drug
treatment, since cases (mostly asymptomatic) closer to the acute
phase of the disease can possibly account for more rapid
seroconversion. Also, statistical limitations of our data analysis
may exist due to the varying age groups and varying times of post-
treatment follow-up in the four projects, as has been examined in
other studies [29]. Finally, differences in immune response among
populations may play a role.
Whatever the reason, the lack of a better marker for indicating
parasitological cure is a major impediment to advances in
treatment and development of more effective drugs [4]. The
observed differences between seroconversion rates in Central and
South America highlight the need for further studies to confirm
our findings and help improve etiological treatment protocols with
dosages and duration adapted to the Chagas disease cycle in
different geographic regions.
Since the start of our first Chagas disease program in 1999,
which focused on young children, MSF has pushed to deliver
diagnosis and treatment of this disease to wider and wider age
groups. Over the past decade, treatment for Chagas disease has
Chagas Disease Treatment Programs
www.plosntds.org 7 July 2009 | Volume 3 | Issue 7 | e488expanded from children ,12 years old, to ,15, then ,18, and
finally adults. This strategy has helped bring broader coverage of
treatment delivery for Chagas disease.
Bolivia is the most highly endemic country in the world for T.
cruzi infection, with up to 1.8 million people believed to be infected
[1,30–32]. MSF currently has two active programs in Cocha-
bamba, where Chagas disease treatment is integrated into primary
health care and offered to adults as well as children and
adolescents. Because of high prevalence in Bolivia, Chagas disease
diagnosis and treatment remain an operational priority there for
MSF.
MSF’s programs, both past and present, highlight where and
what the needs are for people affected by Chagas disease. In
addition to increasing public awareness and patient access to
existing diagnostics and drugs, the development of new, less toxic,
more effective drugs; adapted pediatric formulations of treatments;
and a reliable test of parasitological cure are all urgently required.
Because Chagas disease and those afflicted with it are often
neglected, medical care for this patient population should be
implemented whenever and wherever possible, as MSF has
demonstrated as feasible in these four programs, and research
and development for the disease should be scaled up dramatically.
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